What does Cytokinetics do?

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining.

Is omecamtiv mecarbil FDA approved?

The US Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for omecamtiv mecarbil for the treatment of heart failure with reduced ejection fraction (HFrEF). The NDA has been assigned a standard review with a Prescription Drug Use Fee Act (PDUFA) target action date of November 30, 2022.

How does omecamtiv mecarbil work?

Omecamtiv mecarbil activates cardiac myosin and augments the speed of ATP hydrolysis, thus accelerating the production of a strong actin-myosin complex, which leads to increased force production.

Who makes omecamtiv mecarbil?

Cytokinetics
US biotech major Amgen (Nasdaq: AMGN) has returned all development and commercialization rights for omecamtiv mecarbil and AMG 594 to Cytokinetics (Nasdaq: CYTK).

Is cytokinetics a good company?

Cytokinetics is ranked #18 on the Best Companies to Work For in South San Francisco, CA list. Zippia’s Best Places to Work lists provide unbiased, data-based evaluations of companies. Rankings are based on government and proprietary data on salaries, company financial health, and employee diversity.

Where is cytokinetics located?

South San Francisco, California
Cytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.

Is Vericiguat FDA approved?

In a press release on January 20, 2021, Merck announced that the FDA has approved Verquvo (vericiguat), the soluble guanylate cyclase (sGC) stimulator to diminish the risk of cardiovascular death and heart-failure hospitalization following hospitalization for heart failure or need for outpatient IV diuretics in adults …

Is Mavacamten FDA approved?

FDA has approved Camzyos (mavacamten) capsules to treat adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (oHCM) to improve exercise capacity and symptoms.

Has Mavacamten been approved by FDA?

How does nesiritide work in the body?

Nesiritide works by facilitating cardiovascular homeostasis through the negative regulation of the renin-angiotensin-aldosterone system. This regulation will in order stimulate cyclic guanosine monophosphate and smooth muscle cell relaxation. In simpler terms, it promotes vasodilation, natriuresis, and diuresis.

Does Verquvo improve ejection fraction?

Verquvo® (vericiguat) Approved to Treat Heart Failure With Reduced Ejection Fraction. The U.S. Food and Drug Administration (FDA) has approved Verquvo® (vericiguat) for heart failure with reduced ejection fraction (HFrEF).